FOLFOX4治疗晚期肝癌的临床研究

目的:观察FOLFOX4方案治疗晚期肝癌的疗效。方法:72例晚期肝癌患者，分为治疗组与对照组。治疗组采用FOLFOX4方案化疗，对照组采用最佳支持治疗。参照RECIST标准对该方案疗效进行评估，按照WHO抗癌药物毒副反应的分度标准评价毒副反应。结果:治疗组中40例晚期肝癌患者均可评价疗效，共完成化疗109个周期。肿瘤完全缓解（CR）0例，部分缓解（PR）8例，稳定（SD）19例，进展（PD）13例。CR+PR率20.0%，总有效率67.5%。不良反应主要为胃肠道反应、骨髓抑制及外周神经毒性，对症治疗可缓解，均可以耐受。结论:FOLFOX4方案治疗晚期肝癌临床疗效满意，安全性高，毒副反应轻，值得临床推广应用。

Clinical study of FOLFOX4 regimen for patients with advanced hepatocellular carcinoma

Objective:To observe the efficiency of FOLFOX4 regimen in the patients with advanced hepatocellular carcinoma（HCC).Methods:All 72 patients with advanced HCC were divided into treatment group and the control group，treatment group were given systemic chemotherapy with FOLFOX4 regimen，the control group were given the best supportive treatment．The outcomes and the toxicity were evaluated by RECIST criterion and WHO standard for anticancer drugs toxicity.Results:All 40 patients of treatment group were successfully evaluated，completed 109 chemotherapy circles in total.None of the patients had a complete response to treatment，8 patients obtained partial response，19 patients stable disease，13 patients disease progression.The rate of CR+PR was 20.0%，the total effective rate was 67.5%.The side effects mainly were digestive tract reaction，bone marrow depression and neurotoxicity，which could be relieved after symptomatic treatment.Conclusion:FOLFOX4 is a safe and effective therapy regimen for patients with advanced HCC.